Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clonal analysis of B-cell response in pemphigus course: toward more effective therapies.

Literature DB >> 25666671

Clonal analysis of B-cell response in pemphigus course: toward more effective therapies.

Abstract

In this issue, Hammers et al. report the first longitudinal study of B-cell responses in pemphigus vulgaris. They show persistence of the same sets of anti-desmoglein 3 (Dsg3) B-cell clones over time in two patients with active disease, suggesting that escape from tolerance is not a frequent event. In addition, the disappearance of anti-Dsg3 B-cell clones in two patients during long-term rituximab-induced remission supports the therapeutic potential of rituximab.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 25666671 DOI： 10.1038/jid.2014.499

Source DB: PubMed Journal: J Invest Dermatol ISSN： 0022-202X Impact factor: 8.551

16 in total

1. Pathogenic human monoclonal antibody against desmoglein 3.

Authors: Shih-Wei Yeh; Lisa A Cavacini; Kailash C Bhol; Mong-Shang Lin; Mukesh Kumar; Mark Duval; Marshall R Posner; A Razzaque Ahmed
Journal: Clin Immunol Date: 2006-04-25 Impact factor: 3.969

2. Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity.

Authors: Jun Yamagami; Aimee S Payne; Stephen Kacir; Ken Ishii; Don L Siegel; John R Stanley
Journal: J Clin Invest Date: 2010-10-18 Impact factor: 14.808

3. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.

Authors: Natacha Colliou; Damien Picard; Frédérique Caillot; Sébastien Calbo; Stéphanie Le Corre; Annick Lim; Brigitte Lemercier; Brigitte Le Mauff; Maud Maho-Vaillant; Serge Jacquot; Christophe Bedane; Philippe Bernard; Frédéric Caux; Catherine Prost; Emmanuel Delaporte; Marie-Sylvie Doutre; Brigitte Dreno; Nathalie Franck; Saskia Ingen-Housz-Oro; Olivier Chosidow; Christine Pauwels; Catherine Picard; Jean-Claude Roujeau; Michèle Sigal; Emmanuelle Tancrede-Bohin; Isabelle Templier; Rüdiger Eming; Michael Hertl; Michel D'Incan; Pascal Joly; Philippe Musette
Journal: Sci Transl Med Date: 2013-03-06 Impact factor: 17.956

Review 4. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab.

Authors: K T Amber; M Hertl
Journal: J Eur Acad Dermatol Venereol Date: 2014-09-03 Impact factor: 6.166

5. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface.

Authors: Giovanni Di Zenzo; Giulia Di Lullo; Davide Corti; Valentina Calabresi; Anna Sinistro; Fabrizia Vanzetta; Biagio Didona; Giuseppe Cianchini; Michael Hertl; Rudiger Eming; Masayuki Amagai; Bungo Ohyama; Takashi Hashimoto; Jerry Sloostra; Federica Sallusto; Giovanna Zambruno; Antonio Lanzavecchia
Journal: J Clin Invest Date: 2012-09-04 Impact factor: 14.808

Clonal analysis of B-cell response in pemphigus course: toward more effective therapies.

1. Pathogenic human monoclonal antibody against desmoglein 3.

2. Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity.

3. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.

Review 4. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab.

5. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface.

6. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

7. Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: correlation with disease progression.

8. Specific peripheral B cell tolerance defects in patients with multiple sclerosis.

Review 9. Desmoglein as a target in skin disease and beyond.

10. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.

Review 1. Humoral Epitope Spreading in Autoimmune Bullous Diseases.